Jianxin Superconductivity (688805.SH), a core component research and development company for medical magnetic resonance imaging (MRI) equipment, plans to publicly issue 41.92 million shares

According to the Zhitong Finance App, Jianxin Superconductivity (688805.SH) disclosed a prospectus. The company plans to publicly issue 41.92 million shares, accounting for 25% of the total share capital after issuance. Senior management and core employees plan to participate in this strategic placement through an asset management plan. The number of participants in the strategic placement will not exceed 10% of the scale of this public offering, or 4.192 million shares, while the maximum subscription amount will not exceed 84.35 million yuan. Guangfa Qianhe Investment Co., Ltd. participated in the strategic placement of this offering. The initial follow-up ratio is expected to be 5% of the current issuance, or 2,096 million shares. The initial inquiry date for this offering is December 10, 2025, and the subscription date is December 15, 2025. The application for listing on the Science and Technology Innovation Board will be made as soon as the distribution is over.

The company is mainly engaged in R&D, production and sales of core components for medical magnetic resonance imaging (MRI) equipment. The main products include superconducting magnets, permanent magnets and gradient coils, which account for about 50% of the cost of core components of MRI equipment. With the mission of “making magnetic resonance an affordable daily diagnosis method for ordinary people”, the company promotes the iterative progress and promotion and popularization of magnetic resonance through independent research and development and continuous innovation.

The company's net profit from 2022 to 2024 attributed to the owner of the parent company was 346.35 million yuan, 487.347 million yuan, and 557.839 million yuan, respectively. Benefiting from factors such as increased revenue volume of liquid helium-free superconducting products, continued deepening cooperation with key customers, and the gradual release of domestic medical equipment procurement demand, the company expects its business performance to grow rapidly in 2025. The company expects to achieve operating income of 580 million yuan to 620 million yuan, an increase of 36.31% to 45.71% year on year; net profit attributable to shareholders of the parent company after deducting non-recurring profit and loss is estimated to be 70 million yuan to 75 million yuan, an increase of 39.25% to 49.20% year on year.

The capital raised by the company will invest in a project with an annual output of 600 sets of liquid-free helium superconducting magnets, a technical improvement project with an annual output of 600 sets of high-field strength medical superconducting magnets, and a new superconducting magnet research and development project. The capital raised by the company revolves around the company's main business, focusing on national strategies and major needs, further increasing investment in R&D and innovation, further improving the industrial chain and product structure, and enhancing the competitiveness of the company's products and technology.